Applications of MRS in the evaluation of focal malignant brain lesions

Cancer Imaging

Volumn 6, Issue 1, 2006, Pages 95-99

  Delorme, S ^a   Weber, M A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Brain neoplasms; Magnetic resonance spectroscopy; Radiotherapy

Indexed keywords

DIAGNOSTIC AGENT;

ARTICLE; BRAIN TUMOR; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

BRAIN NEOPLASMS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 33746399737     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2006.0015     Document Type: Article

References (6)

1. Bachert P, Schröder L. Magnetresonanzspektroskopie. Teil 1: Grundlagen. Radiologe 2003; 43: 1113-26; quiz 1127-8.
2. Bachert P, Lichy MP. Magnetresonanzspektroskopie. Teil 2: Anwendung in Diagnostik und klinischer Forschung. Radiologe 2004; 44: 81-95.
3. Law M. MR spectroscopy of brain tumors. Top Magn Reson Imaging 2004; 15: 291-313.
4. Law M, Yang S, Wang H. Glioma grading: sensitivity, specificity and predictive values of perfusion MRI imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol 2003; 24: 1989-98.
5. Fuss M, Wenz F, Essig M, Muenter M, Debus J, Herman TS et al. Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy. Int J Radiat Oncol Biol Phys 2001; 51: 478-82.
6. Schlemmer HP, Bachert P, Herfarth KK, Zuna I, Debus J, van Kaick G. Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. Am J Neuroradiol 2001; 22: 1316-24.